Feed excerpt — reported by STAT News
Roche drug, which inhibits G12C KRAS mutations in second-line advanced non-small cell lung cancer, outpaced offerings from Amgen and Bristol Myers Squibb.
MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at STAT News →